Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback